Command Palette
Search for a command to run...
Krsnaa Diagnostics
NSE: KRSNAABSE: 543328HEALTHCAREHEALTHCARE SERVICES
Market Cap
--
P/E Ratio
0.00
P/B Ratio
0.00
ROE
0.00%
ROA
0.00%
Debt/Equity
0.00
Book Value
₹0.0
EPS
₹0.0
About Krsnaa Diagnostics
Krsnaa Diagnostics is primarily engaged in the business of providing Diagnostic Services primarily in relation to Pathology Investigation, Radiology Investigation and Tele reporting.
Krsnaa Diagnostics Limited was originally incorporated as `Krsna Diagnostics Private Limited' at Pune, Maharashtra dated December 22, 2010. The Company name was changed to `Krsnaa Diagnostics Private Limited', pursuant to a fresh Certificate of Incorporation issued by the RoC on January 29, 2015. Thereafter, the status got converted into a Public Company and the name was changed to Krsnaa Diagnostics Limited pursuant to a fresh Certificate of Incorporation issued by the RoC on 06 May, 2021. The Company is primarily engaged in providing diagnostic services centres all over India. The Company is providing Radiology and Pathology services for X-ray, CT Scan, MRI, Mammography, Bone Densitometry, Ultrasound, Colout Doppler, Tele-Reporting services, all type of blood and urine investigation and other related diagnostic services. The Company owns an extensive network of integrated diagnostics centres across India primarily in non-metro and lower-tier cities and towns, with operating 1823 diagnostics centres offering radiology and pathology services in 13 states across the country. The Company started operating 12 centres in Himachal Pradesh via public private partnership (PPP) in 2012. It installed 50 centres in 2017 and expanded operations across 13 states in 2018. Further, it expanded the operations to over 1500 centres across India in 2020. The Company in August 2021, came up with an Initial Public Offer of 12,741,036 Equity Shares by raising funds from public aggregating to Rs.1213.33 Crore, comprising a Fresh Issue of 4,215,516 Equity Shares aggregating to Rs 400 Crore and an Offer for Sale of 8,525,520 Equity Shares aggregating to Rs. 813.33 Crore. The Company operationalized 26 radiology centers, 50 pathology labs, and 556 collection centers in 2022-23. It expanded geographical presence from 660+ centers in FY 2018 to over 2,800 centers in FY 2023. The Teleradiology hub in Pune achieved prestigious accreditation from the National Accreditation Board for Hospitals & Healthcare Providers (NABH) during the year 2023. The Company expanded its geographical presence to more than 3600 centres in FY 2024. It expanded into Jharkhand with the launch of two new centres, by establishing over 600 collection centres in 2025. 40 CT scan units have been commissioned in Maharashtra, with MRI and additional CT installations in progress in FY 2025. In FY2025, retail operations were launched across four states and within a short span, the Company's network expanded from 1,600+ to over 2,400 touchpoints. The Company acquired a 23.53% stake in Apulki Healthcare, making the Company an exclusive diagnostic partner with oncology and cardiac care hospitals in 2025.
Price Action • KRSNAA
Financial Statements
Consolidated & Standalone Reports
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 |
|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 720.26 | 707.36 | 606.82 | 483.49 | 469.82 | 661.48 | 193.18 | 149.22 | 91.98 | 60.71 |
Operating Expenses | 489.01 | 485.04 | 443.86 | 339.84 | 320.34 | 302.64 | 118.61 | 87.14 | 61.42 | 42.37 |
Operating Profit | 209.3 | 196.66 | 146.16 | 124.25 | 134.55 | 93.81 | 64.28 | 59.77 | 29.17 | 14.52 |
Operating Margin (%) | - | 27.8 | 24.09 | 25.7 | 28.64 | 14.18 | 33.28 | 40.06 | 31.71 | 23.92 |
Total Expenses | - | 597.76 | 534.87 | 401.3 | 380.22 | 366.02 | 175.56 | 128.58 | 86.57 | 58.45 |
EBITDA | - | 222.33 | 162.96 | 143.66 | 149.48 | 358.83 | 74.57 | 62.09 | 30.57 | 18.34 |
EBITDA Margin (%) | - | 31.43 | 26.85 | 29.71 | 31.82 | 54.25 | 38.6 | 41.61 | 33.23 | 30.21 |
Interest Expenses | 27.24 | 24.57 | 16.47 | 7.68 | 18.49 | 25.94 | 24.61 | 15.89 | 7.72 | 6.22 |
Depreciation | 89.47 | 88.16 | 74.55 | 53.78 | 41.39 | 37.44 | 32.33 | 25.56 | 17.43 | 9.86 |
Profit Before Tax (PBT) | 114.55 | 109.6 | 71.95 | 82.19 | 89.6 | 295.45 | 17.62 | 20.64 | 5.41 | 2.25 |
Tax Expenses | 29.08 | 26.79 | 13.38 | 18.68 | 18.9 | 110.52 | 5.15 | 8.17 | 0.55 | 0.18 |
PAT Before Extraordinary Items | - | 82.81 | 58.56 | 63.51 | 70.7 | 184.93 | 12.47 | 12.47 | 4.86 | 2.07 |
Net Profit | 85.47 | 82.81 | 58.56 | 63.51 | 70.7 | 184.93 | 12.47 | 12.47 | 4.86 | 2.07 |
Net Profit Margin (%) | - | 12.14 | 9.92 | 13.68 | 15.54 | 46.64 | 6.82 | 8.48 | 5.36 | 3.64 |
EPS (Adjusted) | - | 25.53 | 18.05 | 19.58 | 21.8 | 57.01 | 3.85 | 3.84 | 1.5 | 0.64 |
Valuation & Key Ratios
Performance Metrics
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 |
|---|---|---|---|---|---|---|---|---|---|---|
Book Value Per Share | - | 276.65 | 252.47 | 236.48 | 218.72 | -16.2 | 117.09 | 93.04 | 30.19 | 20.77 |
Return on Assets (ROA) % | - | 6.45 | 4.99 | 6.98 | 8.06 | 30.59 | 2.28 | 2.52 | 1.79 | 1.17 |
Return on Equity (ROE) % | - | 9.26 | 7.18 | 8.55 | 10.29 | -1,757.04 | 20.63 | 25.94 | 31.2 | 19.32 |
Return on Capital Employed (ROCE) % | - | 13.63 | 9.87 | 11.03 | 14.81 | 76.39 | 11.61 | 11.39 | 8.46 | 6.11 |
Profitability Ratios | - | - | - | - | - | - | - | - | - | - |
Liquidity Ratios | - | - | - | - | - | - | - | - | - | - |
Valuation Ratios | - | - | - | - | - | - | - | - | - | - |
Debt to Equity Ratio | - | 0.19 | 0.13 | 0.02 | 0.04 | -19.26 | 3.84 | 3.45 | 5.32 | 3.02 |
Featured Insight
No recent news available
Key People
M
Mr. Mitesh Dave
Group Chief Executive Officer
M
Mr. Pawan Daga
Chief Financial Officer
M
Mr. Sujoy Sudipta Bose
Company Secretary,Compliance Officer
M
Mr. Vivek Jain
Head(Investor Relations)